GlaxoSmithKline (CAI:BIOC) Total Operating Expense: E£204 Mil (TTM As of Sep. 2016)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is GlaxoSmithKline Total Operating Expense?

GlaxoSmithKline CAI:BIOC +20.00% Total Operating Expense is E£204 Mil as of Sep. 2016.

GlaxoSmithKline's Total Operating Expense for the three months ended in Sep. 2016 was E£63 Mil. GlaxoSmithKline's Total Operating Expense for the trailing twelve months (TTM) ended in Sep. 2016 was E£204 Mil.

GlaxoSmithKline Total Operating Expense Related Terms

GlaxoSmithKline Total Operating Expense Historical Data

* Premium members only.

The historical data trend for GlaxoSmithKline's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GlaxoSmithKline Total Operating Expense Chart

GlaxoSmithKline Annual Data
Trend Dec12 Dec13 Dec14 Dec15
Total Operating Expense
228.63 265.80 239.41 240.42

GlaxoSmithKline Quarterly Data
Dec12 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 44.89 26.63 42.63 70.87 63.49

GlaxoSmithKline Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Sep. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was E£204 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of E£204 Mil mean?
GlaxoSmithKline (CAI:BIOC) has a Total Operating Expense of E£204 Mil as of Sep. 2016. Total operating expense is the primary recurring expense associated with central operations. View historical data on GlaxoSmithKline and its competitors.
Is GlaxoSmithKline's Total Operating Expense too high?
GlaxoSmithKline's current Total Operating Expense is E£204 Mil.
How does GlaxoSmithKline's Total Operating Expense compare to PRPH?
GlaxoSmithKline's Total Operating Expense of E£204 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Drug Manufacturers company?
A good Total Operating Expense depends on the Drug Manufacturers industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on GlaxoSmithKline and its competitors. GlaxoSmithKline's current Total Operating Expense is E£204 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline stock overvalued right now?
GlaxoSmithKline (CAI:BIOC) has a current Total Operating Expense of E£204 Mil. The current Total Operating Expense is E£204 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For GlaxoSmithKline (CAI:BIOC), the current Total Operating Expense is E£204 Mil as of Sep. 2016. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

GlaxoSmithKline Business Description

Address Boomerang Building, No 46, Block (J) First Section City Centre, Town Centre, Second floor, Fifth District - New Cairo, Cairo, EGY, 11835
GlaxoSmithKline is a pharmaceutical company. It is focused on developing new medicines in respiratory, HIV, oncology, and immune-inflation. The company is segmented into Commercial Operations and Total Research and development. It generates the majority of its revenue from the Commercial Operations segment.